TY - JOUR
T1 - An early rise in urine N-telopeptide predicts the growth response of normal prepubertal short children to growth hormone therapy
AU - Phillip, M.
AU - Hershkovitz, E.
AU - Limoni, Y.
AU - Leiberman, E.
AU - Belotserkovsky, O.
AU - Douvdevani, A.
AU - Weber, D.
PY - 1996
Y1 - 1996
N2 - The effects of growth hormone (GH) therapy on biochemical markers of bone turnover were investigated in 11 short prepubertal children without GB[ deficiency by measuring serum osteocalcin, a marker for bone formation, and urinary concentrations of pyridinium crosslinked amino acids of collagen (PCL), and the peptide-bound pyridinoline residue N-telopeptide (NT), which are specific markers for bone resorption, GH treatment for three months increased bone turnover in this group of children: urinary PCL concentrations increased from 69 ± 6.2 to 114 ± 9.3 nmol/mmol Cr (p < 0.01), and urinary NT levels increased from 512 ± 65 to 766 ± 74 pmol BCE/μmol Cr (p = 0.058). Serum osteocalcin concentrations increased from 13.64 ± 2.57 ng/ml to 26.45 ± 1.39 ng/ml (p < 0.01). The increment in 12-hour urinary concentrations of PCL was highly correlated with the increment in 12-hour urinary NT levels (r = 0.92, p < 0.01), Stepwise multiple regression analysis revealed that the urinary concentrations of NT after 3 months of GH therapy were the best predictor of growth after 12 months of treatment (r = 0.78, F = 7.9, p = 0.037).
AB - The effects of growth hormone (GH) therapy on biochemical markers of bone turnover were investigated in 11 short prepubertal children without GB[ deficiency by measuring serum osteocalcin, a marker for bone formation, and urinary concentrations of pyridinium crosslinked amino acids of collagen (PCL), and the peptide-bound pyridinoline residue N-telopeptide (NT), which are specific markers for bone resorption, GH treatment for three months increased bone turnover in this group of children: urinary PCL concentrations increased from 69 ± 6.2 to 114 ± 9.3 nmol/mmol Cr (p < 0.01), and urinary NT levels increased from 512 ± 65 to 766 ± 74 pmol BCE/μmol Cr (p = 0.058). Serum osteocalcin concentrations increased from 13.64 ± 2.57 ng/ml to 26.45 ± 1.39 ng/ml (p < 0.01). The increment in 12-hour urinary concentrations of PCL was highly correlated with the increment in 12-hour urinary NT levels (r = 0.92, p < 0.01), Stepwise multiple regression analysis revealed that the urinary concentrations of NT after 3 months of GH therapy were the best predictor of growth after 12 months of treatment (r = 0.78, F = 7.9, p = 0.037).
KW - Bone turnover
KW - Growth hormone
KW - Growth response
KW - N-telopeptide
KW - Osteocalcin
KW - Pyridinium cross-links
UR - http://www.scopus.com/inward/record.url?scp=0029906584&partnerID=8YFLogxK
U2 - 10.1515/JPEM.1996.9.5.519
DO - 10.1515/JPEM.1996.9.5.519
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 8961127
AN - SCOPUS:0029906584
SN - 0334-018X
VL - 9
SP - 519
EP - 521
JO - Journal of Pediatric Endocrinology and Metabolism
JF - Journal of Pediatric Endocrinology and Metabolism
IS - 5
ER -